Literature DB >> 3042048

Correlated flow cytometric analysis of H-ras p21 and nuclear DNA in multiple myeloma.

H Tsuchiya1, J Epstein, P Selvanayagam, J R Dedman, G Gallick, R Alexanian, B Barlogie.   

Abstract

Correlated analysis of the H-ras oncogenes product (p21) and of nuclear DNA content was performed by flow cytometry (FCM) in patients with DNA-aneuploid multiple myeloma (MM). Bone marrow cells from normal donors and MM patients in remission served as controls. Seventy-four percent of 23 patients with active MM had higher p21 fluorescence in aneuploid tumor cells than were observed in normal donor or myeloma remission bone marrows; 39% of the 23 patients also showed high H-ras p21 expression in diploid cells. There was an inverse relationship between p21 levels and the presence of trisomy 11; especially high p21 levels were noted in patient without trisomy 11. The frequent elevation of p21 protein in aneuploid plasma cells suggests the involvement of the H-ras oncogene in the pathophysiology of MM, which is further supported by a shorter survival among patients with high p21 levels.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3042048

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

1.  Multiple myeloma: biology and therapy.

Authors:  B Barlogie; J Epstein
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

Review 2.  Neuroblastoma stage IV-S.

Authors:  T D Miale; K Kirpekar
Journal:  Med Oncol       Date:  1994       Impact factor: 3.064

3.  Ras oncogene expression and DNA content in plasma cell dyscrasias: a flow cytofluorimetric study.

Authors:  M Danova; A Riccardi; G Ucci; R Luoni; M Giordano; G Mazzini
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640

4.  The proliferation of multiple myeloma colonies (MY-CFUc) in vitro is independent of prognosis and is not associated with mutated N- or K-ras alleles in human bone marrow aspirates.

Authors:  B C Millar; J B Bell; R Barfoot; M Everard
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

5.  Ras oncogene mutation in multiple myeloma.

Authors:  A Neri; J P Murphy; L Cro; D Ferrero; C Tarella; L Baldini; R Dalla-Favera
Journal:  J Exp Med       Date:  1989-11-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.